NASDAQ:CLDX - Celldex Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.5822 -0.01 (-1.69 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$0.5822
Today's Range$0.58 - $0.6026
52-Week Range$0.58 - $3.26
Volume3.86 million shs
Average Volume2.54 million shs
Market Capitalization$85.25 million
P/E Ratio-0.73
Dividend YieldN/A
Beta2.47
Celldex Therapeutics logoCelldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLDX
CUSIP15117B10
Phone908-200-7500

Debt

Debt-to-Equity RatioN/A
Current Ratio5.45
Quick Ratio5.45

Price-To-Earnings

Trailing P/E Ratio-0.73
Forward P/E Ratio-0.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.74 million
Price / Sales6.55
Cash FlowN/A
Price / CashN/A
Book Value$1.74 per share
Price / Book0.33

Profitability

EPS (Most Recent Fiscal Year)($0.80)
Net Income$-93,030,000.00
Net Margins-1,157.96%
Return on Equity-47.36%
Return on Assets-33.16%

Miscellaneous

Employees197
Outstanding Shares143,390,000

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The biopharmaceutical company earned $4.07 million during the quarter, compared to analysts' expectations of $2.03 million. Celldex Therapeutics had a negative net margin of 1,157.96% and a negative return on equity of 47.36%. View Celldex Therapeutics' Earnings History.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Celldex Therapeutics.

What price target have analysts set for CLDX?

6 brokerages have issued 12-month price objectives for Celldex Therapeutics' shares. Their predictions range from $2.00 to $10.00. On average, they anticipate Celldex Therapeutics' stock price to reach $4.50 in the next year. View Analyst Ratings for Celldex Therapeutics.

What are Wall Street analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:
  • 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline received a major setback with failure of its lead pipeline candidate, glembatumumab vedotin, in a breast cancer study. Following the failure, the company discontinued the development of the candidate across all indications. With no approved products, further pipeline setbacks will severely impact Celldex. The company is now focusing on other promising candidates in its pipeline including varlilumab. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, Celldex depends entirely on product development, licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Also, shares of the company have significantly underperformed the industry so far this year." (6/19/2018)
  • 2. Cowen Inc analysts commented, "We spoke with the company who clarified that it remains comfortable on what it has said about dosing for VY-AADC. We believe eventual dosing for the pivotal Phase 2/3 trial could come in between the doses used in the initial Phase 1b, i.e., between 1.5×10 12 to 4.5×10 12 vg in 900µl/putamen. Separately, VYGR has submitted a 510(k) device application in Mar-18 for its own Guide (V-TAG) that could serve as an alternative to the ClearPoint magnetic resonance imaging (MRI) compatible device used in the procedures so far; 10-K expected a V- TAG filing in 1H18. As such, we view this pullback as a particularly good opportunity to BUY this volatile stock." (5/10/2018)
  • 3. Cantor Fitzgerald analysts commented, "Glemba is a Miss. The METRIC trial evaluating metastatic TNBC patients that overexpress gpNMB versus capecitibine did not achieve statistical significance, with glemba-treated patients experiencing PFS of 2.7 months versus 2.6 months for capecitibine, p=0.76. Additionally, significance was not achieved for key secondary endpoints of OR (overall response), DoR (Duration of Response) or OS (Overall Survival)." (4/17/2018)

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:
  • Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 56)
  • Dr. Tibor Keler Ph.D., Founder, Chief Scientific Officer and Exec. VP (Age 59)
  • Ms. Elizabeth Crowley, Chief Product Devel. Officer and Sr. VP (Age 46)
  • Mr. Sam Martin, Sr. VP, CFO, Principal Accounting Officer & Treasurer
  • Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin.

Has Celldex Therapeutics been receiving favorable news coverage?

Media headlines about CLDX stock have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.19 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.04%), Dimensional Fund Advisors LP (2.91%), TSP Capital Management Group LLC (1.00%), JPMorgan Chase & Co. (0.69%), State of Wisconsin Investment Board (0.51%) and Schwab Charles Investment Management Inc. (0.40%). View Institutional Ownership Trends for Celldex Therapeutics.

Which major investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Celldex Therapeutics.

Which major investors are buying Celldex Therapeutics stock?

CLDX stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, JPMorgan Chase & Co., BlackRock Inc. and TSP Capital Management Group LLC. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $0.5822.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $85.25 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-93,030,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Celldex Therapeutics employs 197 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]


MarketBeat Community Rating for Celldex Therapeutics (CLDX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  612
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.